CD274 and retinoblastoma: In summary, overall pCR rates were comparable to neoadjuvant chemotherapy, which enriched to 50% in PD-L1 positive patients, and to 90% in PD-L1 positive patients with additional DNA damage repair (DDR) or retinoblastoma (RB1) genomic alteration.